Erythropoietin. Known as EPO MW 30400Da Discovered by Miyake et al 1977from urine of anaemic pts. LC 4 alpha helical bundle class 1 cytokine 193 a.a. human (192 mouse) When levels low e.g.in CRF, chemotherapy treatment in cancer
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Enables the use of Epo in therapy for CRF and cancer without unwanted immunological effects
synthesised from random peptide ‘libraries’ displayed on filamentous phages ( Bacterial virus)
These bind to and activate a receptor of cytokines similarly to original cytokine.
14-20 a.a. In length, serve as lead compounds for development of therapeutically effective Epo,smaller, less side effectsPeptide Mimetics
May be used in treatment of stroke victims
Protects against RBC apoptosis with NFkB stimulation
and abuses !